Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $11.00 target price on the stock.

Can-Fite BioPharma Stock Up 4.9%

NYSE:CANF opened at $0.66 on Tuesday. The stock’s 50 day moving average price is $0.84 and its 200 day moving average price is $1.15. The company has a market capitalization of $2.34 million, a PE ratio of -0.37 and a beta of 1.06. Can-Fite BioPharma has a 52-week low of $0.63 and a 52-week high of $3.12.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.